Conferences - Results from #8560

GU Cancers Symposium 2014 - Second-line prescribing preferences of U.S.-based medical oncologists following first-line TKI in patients with metastatic clear cell renal cell carcinoma - Poster February 4, 2014

GU Cancers Symposium 2014 - Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer analysis - Poster February 4, 2014

GU Cancers Symposium 2014 - Premature termination of genitourinary cancer clinical trials - Poster February 4, 2014

GU Cancers Symposium 2014 - Consideration of height-based rather than weight-based dosing as a more appropriate method of treating with radium-223 - Poster February 4, 2014

GU Cancers Symposium 2014 - Clinical and biologic factors for immune response to sipuleucel-T for metastatic castrate-resistant prostate cancer - Poster February 4, 2014

GU Cancers Symposium 2014 - Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients - Poster February 4, 2014

GU Cancers Symposium 2014 - Predicting radical prostatectomy outcome among men who upgrade from clinical Gleason 6 to pathologic Gleason 7 - Poster February 4, 2014

GU Cancers Symposium 2014 - The effect of cell cycle progression score on treatment decisions in prostate cancer: Results of an ongoing registry trial - Poster February 4, 2014

GU Cancers Symposium 2014 - Cell cycle progression score to predict metastatic progression of clear cell renal cell carcinoma after resection - Poster February 4, 2014

GU Cancers Symposium 2014 - Prognostic utility of the cell cycle progression score generated from needle biopsy in men treated with prostatectomy - Poster February 4, 2014

GU Cancers Symposium 2014 - Prospective evaluation of prescribing preferences by U.S.-based oncologists in the postdocetaxel mCRPC patient - Poster February 4, 2014

GU Cancers Symposium 2014 - Evaluating the safety of abiraterone acetate and docetaxel administered in combination in patients with metastatic castration-resistant prostate cancer - Poster February 4, 2014

GU Cancers Symposium 2014 - An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post-chemotherapy - Poster February 4, 2014

GU Cancers Symposium 2014 - Poster: Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with mCRPC... February 4, 2014

GU Cancers Symposium 2014 - Poster: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study February 4, 2014

GU Cancers Symposium 2014 - Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients - Poster February 4, 2014

GU Cancers Symposium 2014 - CCP score and risk stratification for prostate cancer patients at biopsy - Poster February 4, 2014

GU Cancers Symposium 2014 - NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer - Poster February 4, 2014

GU Cancers Symposium 2014 - Association of alkaline phosphatase with clinical outcomes in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Poster February 4, 2014

GU Cancers Symposium 2014 - Model-based investigation of the interplay between abiraterone exposure, prostate-specific antigen kinetics, and overall survival in castration-resistant prostate cancer patients - Poster February 4, 2014

Page 429 of 475

email news signup